Screener
Immix Biopharma, Inc. IMMX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $4,730,152 | $5,442,737 |
| Accrued research and development expenses | 4,402,801 | 3,254,506 |
| Accrued professional services | 206,927 | - |
| Accrued compensation and related expenses | 880,671 | 942,163 |
| Other accrued expenses | 193,715 | 331,801 |
| Total accounts payable and accrued expenses | $10,414,266 | $9,971,207 |
Document
FAQ
- What is Immix Biopharma, Inc.'s accrued expenses?
- Immix Biopharma, Inc. (IMMX) reported accrued expenses of $880.67K in Q1 2026.
- How has Immix Biopharma, Inc.'s accrued expenses changed year-over-year?
- Immix Biopharma, Inc.'s accrued expenses increased by 20.3% year-over-year, from $731.79K to $880.67K.
- What is the long-term trend for Immix Biopharma, Inc.'s accrued expenses?
- Over 3 years (2022 to 2025), Immix Biopharma, Inc.'s accrued expenses has grown at a 29.1% compound annual growth rate (CAGR), from $438.2K to $942.16K.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Immix Biopharma, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude